Gilad Goldhirsh

Statistics

Publications

Citations

H-Index

Active since

2020

Affiliations

Technion – Israel Institute of Technology(Current)

Rambam Health Care Campus

Gilad Goldhirsh is an author at Technion – Israel Institute of Technology specializing in oncology, programmed death-ligand 1 signaling, and checkpoint inhibitor therapy.

ORCID

Publications per year

2020–2024

Publications

Excess of the NF-ĸB p50 subunit generated by the ubiquitin ligase KPC1 suppresses tumors via PD-L1– and chemokines-mediated mechanisms

Yelena Kravtsova‐Ivantsiv, Gilad Goldhirsh, Alexandra Ivantsiv et al. · Proceedings of the National Academy of Sciences · 2020 · 26 citations · Full text

Life Sciences, Molecular Biology, Oncology +16

CXCL12 restricts tumor growth by suppressing the Ras, ERK1/2, c-Myc, and the immune checkpoint PD-L1 pathways

Yelena Kravtsova‐Ivantsiv, Gilad Goldhirsh, Aaron Ciechanover · Proceedings of the National Academy of Sciences · 2024 · 13 citations · Full text

Medicine, Cancer Biology, Oncology +17

Inhibition of nucleo-cytoplasmic proteasome translocation by the aromatic amino acids or silencing Sestrin3—their sensing mediator—is tumor suppressive

Ido Livneh, Bertrand Fabre, Gilad Goldhirsh et al. · Cell Death and Differentiation · 2024 · 12 citations · Full text

Life Sciences, Cancer Biology, Oncology +17

A short binding site in the KPC1 ubiquitin ligase mediates processing of NF-κB1 p105 to p50: A potential for a tumor-suppressive PROTAC

Gilad Goldhirsh, Yelena Kravtsova‐Ivantsiv, Gandhesiri Satish et al. · Proceedings of the National Academy of Sciences · 2021 · 11 citations · Full text

Life Sciences, Molecular Biology, Oncology +13

1–4 of 4